公开(公告)号：EP2305641A4

公开(公告)日：2012-08-22

申请号：EP09770109

申请日：2009-06-22

申请人： ASTELLAS PHARMA INC

发明人： KUBOTA HIDEKI ,  TSUKAMOTO ISSEI ,  KAMIJO KAZUNORI ,  KATO KOJI ,  FUKUDA YUTA ,  AZAMI HIDENORI

IPC分类号： C07C311/21 ,  A61K31/341 ,  A61K31/426 ,  A61K31/427 ,  A61K31/4402 ,  A61K31/4406 ,  A61K31/443 ,  A61K31/4439 ,  A61K31/497 ,  A61K31/501 ,  A61K31/506 ,  A61P13/02 ,  A61P13/08 ,  A61P13/10 ,  A61P43/00 ,  C07D213/71 ,  C07D277/20 ,  C07D277/36 ,  C07D277/56 ,  C07D307/64 ,  C07D405/12

CPC分类号： C07C311/21 ,  A61K31/341 ,  A61K31/426 ,  A61K31/427 ,  A61K31/4402 ,  A61K31/4406 ,  A61K31/443 ,  A61K31/4439 ,  A61K31/497 ,  A61K31/501 ,  A61K31/506 ,  C07C2602/08 ,  C07D213/71 ,  C07D213/80 ,  C07D277/20 ,  C07D277/36 ,  C07D277/56 ,  C07D307/64 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D417/12

公开(公告)号：EP2963036A4

公开(公告)日：2016-08-03

申请号：EP14757377

申请日：2014-02-27

申请人： ASTELLAS PHARMA INC

发明人： TAKAHASHI TAISUKE ,  MAEDA JUN ,  INAGAKI YUSUKE ,  NEGORO KENJI ,  TANAKA HIROAKI ,  YOKOYAMA KAZUHIRO ,  TAKAMATSU HAJIME ,  KOIKE TAKANORI ,  TSUKAMOTO ISSEI

IPC分类号： C07D417/14 ,  A61K31/497 ,  A61K31/5377 ,  A61P13/10 ,  A61P43/00 ,  C07D491/08 ,  C07D491/107

CPC分类号： C07D417/14 ,  A61K31/497 ,  A61K31/5377 ,  C07D491/08 ,  C07D491/107

摘要： [Problem] A compound which is useful as an active ingredient of a pharmaceutical composition for treating storage dysfunctions, voiding dysfunctions, and lower urinary tract diseases is provided. [Means for Solution] The present inventors have found that a thiazole derivative having pyrazine-2-carbonylamino substituted at the 2-position is an excellent muscarinic M 3 receptor positive allosteric modulator, and is useful as an agent for preventing and/or treating bladder or urinary tract diseases, related to bladder contraction by a muscarinic M 3 receptor, thereby completing the present invention. The 2-acylaminothiazole derivative or a salt thereof of the present invention can be used as an agent for preventing and/or treating bladder or urinary tract diseases, related to bladder contraction by a muscarinic M 3 receptor, for example, voiding dysfunctions such as underactive bladder.

公开(公告)号：EP2050446A4

公开(公告)日：2011-02-16

申请号：EP07792264

申请日：2007-08-09

申请人： ASTELLAS PHARMA INC

发明人： KUBOTA HIDEKI ,  TODA SUSUMU ,  TSUKAMOTO ISSEI ,  FUKUDA YUTA ,  WAKAYAMA RYUTARO ,  ONO KAZUKI ,  WATANABE TORU ,  AZAMI HIDENORI

IPC分类号： A61K31/216 ,  A61K31/18 ,  A61K31/195 ,  A61K31/197 ,  A61K31/198 ,  A61K31/235 ,  A61K31/24 ,  A61K31/275 ,  A61K31/341 ,  A61K31/343 ,  A61K31/381 ,  A61K31/40 ,  A61K31/4015 ,  A61K31/404 ,  A61K31/415 ,  A61K31/4196 ,  A61K31/423 ,  A61K31/426 ,  A61K31/44 ,  A61K31/4402 ,  A61K31/4406

CPC分类号： C07C311/29 ,  A61K31/18 ,  A61K31/195 ,  A61K31/197 ,  A61K31/198 ,  A61K31/216 ,  A61K31/235 ,  A61K31/24 ,  A61K31/275 ,  A61K31/341 ,  A61K31/343 ,  A61K31/381 ,  A61K31/40 ,  A61K31/4015 ,  A61K31/404 ,  A61K31/415 ,  A61K31/4196 ,  A61K31/423 ,  A61K31/426 ,  A61K31/44 ,  A61K31/4402 ,  A61K31/4406 ,  C07C311/14 ,  C07C311/19 ,  C07C311/21 ,  C07C311/47 ,  C07C311/51 ,  C07C323/49 ,  C07C2601/02 ,  C07C2601/08 ,  C07C2601/14 ,  C07C2602/08 ,  C07C2602/10 ,  C07D207/27 ,  C07D207/325 ,  C07D209/08 ,  C07D213/40 ,  C07D213/68 ,  C07D213/70 ,  C07D213/79 ,  C07D213/89 ,  C07D215/12 ,  C07D217/06 ,  C07D231/12 ,  C07D237/08 ,  C07D239/26 ,  C07D241/12 ,  C07D249/08 ,  C07D263/32 ,  C07D263/58 ,  C07D277/20 ,  C07D277/28 ,  C07D277/36 ,  C07D295/12 ,  C07D307/52 ,  C07D307/81 ,  C07D333/20 ,  C07D333/34 ,  C07D333/38 ,  C07D333/40 ,  C07D333/58

公开(公告)号：EP1619185A4

公开(公告)日：2008-07-23

申请号：EP04729502

申请日：2004-04-26

申请人： ASTELLAS PHARMA INC

发明人： KOSHIO HIROYUKI ,  TSUKAMOTO ISSEI ,  KAKEFUDA AKIO ,  AKAMATSU SEIJIRO ,  SAITOH CHIKASHI

IPC分类号： C07D223/16 ,  A61K31/55 ,  A61P13/02 ,  A61P43/00 ,  C07D401/06 ,  C07D401/12 ,  C07D403/06 ,  C07D403/12 ,  C07D417/06

CPC分类号： C07D401/06 ,  C07D223/16

摘要： A novel 4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepine derivative represented by the following formula (I) or a pharmaceutically acceptable salt of the derivative. They are useful as a therapeutic or preventive agent for night pollakisuria and/or diabetes insipidus.

公开(公告)号：EP1481977A4

公开(公告)日：2006-02-01

申请号：EP03743518

申请日：2003-02-27

申请人： ASTELLAS PHARMA INC

发明人： IGARASHI SUSUMU ,  NAITO RYO ,  OKAMOTO Y ,  KAWANO NORIYUKI ,  TSUKAMOTO ISSEI ,  SATO IPPEI ,  TAKEUCHI MAKOTO ,  KANOH HIROYUKI ,  KOBORI MASATO

IPC分类号： A61P19/00 ,  A61P19/08 ,  A61P19/10 ,  A61P43/00 ,  C07D487/04 ,  A61K31/5025 ,  A61K31/55 ,  C07D519/00

CPC分类号： C07D487/04

摘要： As the results of intensive studies aiming at developing a remedy which has an effect of promoting osteogenesis by accelerating the function of osteoblasts, it is found out that specific nitrogen-containing heterocyclic compounds show a potent effect of promoting osteogenesis by osteoblasts and thus are useful as excellent preventives or remedies for metabolic bone diseases. Namely, it is intended to provide 3,6-disubstituted-1,2,4-triazo[4,3-b]pyridazine compounds having an effect of promoting osteogenesis or pharmaceutically acceptable salts thereof, and medicinal compositions, in particular, osteogenesis promoters comprising these compounds with a pharmaceutically acceptable carrier.